Scalper1 News
Several key drugs from major drugmakers got endorsements from the European Medicines Agency (EMA) Friday, making commercial approval in the European Union’s enormous market much more likely. Bristol-Myers Squibb’s (BMY) hepatitis C drug daclatasvir, now branded Daklinza, was endorsed by the EMA’s Committee for Medicinal Products for Human Use (CHMP) for use in combination with other hep C drugs, notably Gilead Sciences’ (GILD) Sovaldi. Sovaldi and Scalper1 News
Scalper1 News